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	Abstract	
Dysthyroid	 eye	 disease	 is	 a	 rare	 condition,	mainly	 found	 in	 people	with	 Graves’	 hyperthyroidism.	
Autoimmune	 responses	 to	 thyroid/orbit	 shared	 antigens	 drive	 extensive	 tissue	 remodelling.	 This	
includes	excess	adipogenesis	and	over-production	of	extra-cellular	matrix,	which	both	tend	to	occur	
in	the	earlier	‘active’	inflammatory	stages	of	disease.	With	time	these	give	way	to	fibrosis,	which	has	
a	profound	impact	on	eye	motility	and	may	be	life-long.	Progress	has	been	made	in	identifying	the	
shared	autoantigen(s)	and	the	role	of	specific	T	cells	and	autoantibodies	in	remodelling,	which	have	
facilitated	 development	 of	 novel	 therapies.	 However	 relatively	 little	 is	 known	 of	 the	 autoimmune	
processes	under-pinning	fibrosis	and	currently	there	are	no	adequate	medical	treatments.		
	
Dysthyroid	eye	disease-	vital	statistics	
Dysthyroid	eye	disease	is	also	known	as	thyroid	eye	disease	(TED)	or	Graves’	orbitopathy	(GO)	and	
has	 a	 prevalence	 of	 approximately	 10/10,000	 in	 Europe,	 which	 is	 reducing.	 It	 is	 an	 autoimmune	
disease	and	 consequently	more	 common	 in	women,	 although	when	present	 in	men,	 can	be	more	
severe	(1).		
The	 main	 signs	 and	 symptoms	 include	 periorbital	 oedema,	 lid	 lag,	 proptosis,	 chemosis,	 reduced	
ocular	motility,	reduced	visual	acuity,	diplopia	and	optic	neuropathy	(2).	The	severity	and	activity	of	
TED	 can	 be	 assessed	 using	 a	 variety	 of	 scoring	 systems	whose	 relative	merits	 have	 been	 recently	
reviewed	 (3).	 The	 Clinical	 Activity	 Score	 (CAS)	 and	 VISA	 scale	 (Vision,	 Inflammation,	 Strabismus,	
Appearance)	 reflect	 disease	 activity,	 whereas	 the	 EUGOGO,	 NOSPECS	 (No	 symptoms/signs,	 Only	
signs,	 Soft	 tissue	 involvement,	 Proptosis,	 Extraocular	 muscle	 involvement,	 Corneal	 involvement,	
Sight	loss),	VISA-VSA		scales	and	Ophthalmopathy	Index	measure	severity.		
The	natural	course	of	TED,	as	described	by	Rundle’s	curve,	is	unique	to	each	patient;	all	experience	
an	 initial	 inflammatory	 phase,	 of	 varying	 duration	 and	 severity,	 which	 can	 be	 alleviated	 by	
glucocorticoids.	 The	 disease	 eventually	 burns	 out	 and	 becomes	 amenable	 to	 corrective	 surgery,	
although	 decompression	 may	 be	 necessary	 in	 the	 active	 phase	 to	 avoid	 optic	 neuropathy	 and	
blindness	(4).	TED	has	a	significant	negative	impact	on	quality	of	life,	which	has	been	evaluated	using	
the	 specific	 GO-QOL	 questionnaire	 (5).	 Smoking	 is	 a	major	 risk	 factor	 both	 for	 the	 incidence	 and	
severity	of	 the	condition;	 improved	clinical	outcomes	are	associated	with	patients	who	are	able	to	
quit	(6).	
Evidence	for	an	autoimmune	aetiology?	
The	infiltration	of	immune	cells	into	an	organ	or	tissue	is	indicative	of	autoimmunity.	Such	studies	in	
TED	have	been	hampered	by	 the	paucity	of	 suitable	material	 and	 the	 fact	 that	 surgical	 specimens	
tend	to	be	available	only	at	the	later	‘inactive’	stages	of	disease.	However	an	overview	of	available	
studies	 indicates	 that	both	CD4+	and	CD8+	T	cells	as	well	 as	B	cells	are	present	 in	 the	majority	of	
orbits	 examined.	 T	 cells	 tend	 to	 be	 CD45R+,	 suggesting	 recent	 activation.	 Bahn	 and	 colleagues	
described	predominantly	Th1	cells	 in	early	TED,	evolving	 to	Th2	as	disease	progressed	 (7).	A	more	
recent	report	demonstrated	that	the	 level	of	 infiltration	correlated	with	disease	activity	 (8).	Newly	
differentiated	CD14+	macrophages	are	 found	 in	early	disease	 (9),	whilst	monocytes	and	mast	cells	
have	also	been	identified	and	found	to	stimulate	proliferation	of	orbital	fibroblasts	(OF).		
Which	types	of	dysthyroidism-	how	can	thyroid	disease	affect	the	eye?	
More	 than	 90%	 of	 TED	 have	 concurrent	 Graves’	 disease	 (GD).	 In	 GD,	 autoantibodies	 to	 the	
thyrotropin	 receptor	 (TSHR)	 mimic	 the	 biological	 action	 of	 thyroid	 stimulating	 hormone	 (TSH)	
resulting	in	hyperthyroidism	(10).	Up	to	50%	of	GD	patients	also	have	TED,	which	is	severe	in	3-5%.	
However	some	people	with	TED	have	hypothyroidism	whilst	a	small	proportion	are	euthyroid	(11).	
Of	 interest,	 we	 have	 demonstrated	 the	 presence	 of	 TSHR	 autoantibodies	 even	 in	 euthyroid	 TED,	
although	they	lack	biological	activity	when	measured	using	conventional	assays	(12).	
To	be	considered	a	relevant	thyroid/orbit	shared	autoantigen	it	should	be	(a)	Expressed	in	the	orbit;	
(b)	 Disease	 activity	 should	 correlate	 with	 antibody	 or	 T	 cell	 mediated	 immune	 response	 to	 the	
autoantigen;	 (c)	 TED-like	 disease	 should	 be	 induced	 using	 the	 autoantigen;	 (d)	 Antagonism	of	 the	
autoantigen	should	improve	disease.		
Many	investigators	have	demonstrated	that	the	TSHR	is	expressed	in	orbital	tissues.	Our	own	studies	
reported	that	the	TSHR	is	expressed	in	orbital	fat	(13)	and	is	upregulated	during	the	lineage	specific	
differentiation	of	mesenchymal	stem	cells	into	adipocytes	(14),	discussed	below.	TED	incidence	and	
severity	 correlates	 with	 titres	 of	 autoantibodies	 to	 the	 TSHR	 (15).	 Furthermore	 it	 is	 possible	 to	
induce	 signs	 and	 symptoms	 of	 TED	 by	 immunizing	mice	with	 the	 human	 TSHR-A	 subunit	 and	 the	
model	has	been	reproduced	in	more	than	1	laboratory	(16,	17).		
The	 fact	 that	 some	TED	patients	are	euthyroid	and/or	apparently	 free	of	TSHR	autoantibodies	has	
led	 some	 investigators	 to	 seek	 additional	 thyroid/orbit	 shared	 autoantigens.	 The	 IGF1R	 and	 its	
signalling	 pathways	 have	 been	 the	 subject	 of	 intense	 investigation,	 often	 with	 conflicting	 results.	
Smith	and	colleagues	have	demonstrated	that	autoantibodies	to	the	IGF1R	in	TED	patients	produce	a	
range	of	effects,	including	enhanced	OF	proliferation,	increased	secretion	of	inflammatory	cytokines	
and	 elevated	 production	 of	 GAGs	 (18).	 Others	 find	 little	 evidence	 for	 IGF1R	 autoantibodies	 being	
elevated	in	TED	(19,	20),	whilst	Neumann	and	co-workers	suggest	that	cross-talk	between	the	TSHR	
and	IGF1R,	following	activation	of	the	TSHR,	has	a	central	role	in	TED	pathogenesis	(21).	This	model	
could	 be	 compatible	 with	 the	 dramatic	 improvements	 in	 proptosis	 following	 treatment	 with	 an	
IGF1R	antagonist,	teprotumumab,	reported	by	Smith	et	al	(22).		
Neither	 the	TSHR	nor	 IGF1R	 fulfil	all	 criteria;	disease	activity	correlating	with	 immune	reactivity	 to	
the	IGF1R	is	 lacking	as	 is	evidence	that	TSHR	antagonism	improves	TED.	 	However	treatment	of	an	
unusual	thyroid	cancer	patient	who	also	had	GD	and	TED,	with	a	human	monoclonal	thyroid	blocking	
antibody	(TBAB)	improved	these	disorders.	The	results	are	also	compatible	with	my	view	that	we	do	
not	 need	 any	 additional	 autoantigens	 –	 but	 maybe	 we	 have	 yet	 to	 identify	 TED-specific	 TSHR	
autoantibodies	(12).	
Pathogenetic	mechanisms	operating	in	TED	
The	expansion	of	tissues	within	the	confines	of	the	bony	orbit	are	thought	to	account	for	many	of	
the	signs	and	symptoms	of	disease.	In	the	early	active	phase	this	is	predominantly	via	proliferation	of	
orbital	fibroblasts	(OF);	their	over-production	of	extra-cellular	matrix	(ECM)	and	excess	adipogenesis.	
(23).	Several	authors	have	reported	that	the	basal	rate	of	OF	proliferation	is	higher	in	patients	with	
TED	 compared	with	 normal	 orbits.	 Proliferation	 can	 be	 stimulated	 by	 secreted	 factors	 (e.g.	 IGF1,	
PDGF,	 IL-4)	or	direct	 cell-cell	 contact	 (e.g.CD40-CD154)	with	 immune	cells	 infiltrating	 the	 inflamed	
orbit.	 Cytokines	 secreted	 by	macrophages	 and	mast	 cells,	 such	 as	 TGF-β,	 stimulate	 production	 of	
extra-cellular	 matrix	 components	 including	 hyaluronan	 (HA)	 and	 other	 glycosaminoglycans.	
Adipogenesis	 is	 triggered	 in	vitro	by	hormone	cocktails	 including	agents	 to	 increase	cAMP,	 insulin,	
dexamethasone	and	PPAR-γ	agonists	such	as	rosiglitazone.	High	affinity	endogenous	PPAR-γ	agonists	
have	 yet	 to	 be	 identified,	 potential	 ligands	 such	 as	 lysophosphatidic	 acid	 (16:0	 and	 18:1)	 and	 15-
deoxy-PGJ2	have	low	affinity	(23).	
The	 possibility	 that	 activation	 of	 the	 TSHR	 and/or	 IGF1R	 is	 able	 to	 modulate	 adipogenesis	 and	
production	of	ECM	components	has	also	been	investigated	(see	below).		
What	is	different	about	orbital	fibroblasts?	What	is	the	cellular	target	of	the	autoimmune	response?	
Orbital	 fibroblasts	 are	 derived	 from	 neural	 crest,	 unlike	 fibroblasts	 in	 other	 depots	 which	mainly	
have	 a	 mesenchymal	 origin.	 Recent	 studies	 investigated	 the	 stem-cell	 properties	 of	 OF	 and	
demonstrated	that	 the	majority	are	CD90+	and	CD45-,	which	are	positive	and	negative	markers	of	
stem	 cells	 respectively.	 Furthermore	 OF	 were	 able	 to	 undergo	 adipogenesis,	 chondrogenesis	 and	
myogenesis	 in	 vitro	 in	 appropriate	differentiation	 cocktails	 (24,	 25).	An	additional	 feature	of	OF	 is	
their	expression	of	CD40,	making	them	susceptible	to	activation	by	CD40L	which	is	present	on	T	cells.	
The	CD40-CD40L/CD154	bridge	results	in	HA	generation	by	OF	and	cytokine	release	by	both	OF	and	T	
cells	(26).	
In	most	people	with	TED	OF	are	exposed	to	hyperthyroidism,	i.e.	elevated	circulating	thyroxine	and	
tri-iodothyronine.	 However	 thyroid	 hormones	 were	 shown	 to	 inhibit	 TGF-β	 signalling	 and	 hence	
reduce	 the	 fibrotic	 processes	 in	 liver	 and	 skin,	 both	 in	 vitro	 and	 in	 animal	 models.	 The	 TGF-β	
promoter	contains	thyroid	hormone	response	elements	(27).	
TED	patients’	OF	are	also	exposed	to	TSHR	and	IGF1R	agonists,	TSAB	and	increased	IGF1	respectively,	
which	 activate	 the	 relevant	 signal	 cascades.	 Our	 own	 studies	 indicated	 that	 TSHR	 activation	
stimulated	 the	 early	 phases	 of	 adipogenesis	 (28)	 and	 the	 group	 of	 Rebecca	 Bahn	 reported	 that	 a	
human	monoclonal	TSAB	was	able	 to	replace	 insulin,	when	 inducing	 fat-cell	differentiation	 in	vitro	
(29).	We	 also	 compared	 gene-expression	 profiles	 of	 fibroblasts	 experiencing	 TSHR	 activation	with	
controls	 lacking	this	stimulus.	The	top	two	upregulated	genes	in	the	activated	cell	population	were	
HAS-1	and	HAS-2,	hyaluronan	synthase	1	and	2	respectively,	which	encode	the	enzymes	leading	to	
production	of	HA	(30).	
Activation	of	the	IGF1R	leads	to	increased	OF	proliferation,	secretion	of	pro-inflammatory	cytokines	
and	production	of	ECM	but,	as	discussed	above,	whether	IGF1R	autoantibodies	exist	which	are	able	
to	stimulate	signalling	via	the	receptor	remains	an	open	question	(18).	
CD90/Thy-1;	more	than	a	surface	marker?	
As	noted	above,	the	majority	of	OF	are	CD90+;	CD90	is	also	known	as	Thy-1,	which	is	a	glycoprotein	
attached	to	the	cell	surface	via	a	GPI	anchor,	hence	it	is	connected	to	the	cell	via	lipid	rafts.	Thy-1	is	
heavily	 glycosylated	 and	has	 a	molecular	weight	 of	 25-37kD;	 as	 an	 ‘outward	 facing	molecule’	 it	 is	
able	 to	 integrate	 a	 variety	 of	 extra-cellular	 signals.	 To	 facilitate	 this	 Thy-1	 participates	 in	 several	
signalling	 cascades,	 including	 those	 involving	 receptor	 tyrosine	 kinases,	 Ca++	 flux	 and	 G	 protein	
coupled	 receptors	 (GPCR,	 the	 TSHR	 is	 an	 example	 of	 a	GPCR).	 Thy-1	 also	 interacts	with	 the	 ECM,	
notably	integrins	and	syndecan	and	loss	of	Thy-1	expression	is	associated	with	re-programming	(31).		
This	last	is	relevant	to	TED,	in	which	Thy-1+	OF	have	been	shown	to	respond	to	TGFβ	stimulation	by	
acquiring	 α-smooth	muscle	 actin	 (α-SMA)	 expression	 and	 a	myofibroblast	 phenotype.	 In	 contrast	
Thy-1-	OF	respond	to	pro-adipogenic	factors	such	as	cAMP	and	PPARγ	ligands	and	differentiate	into	
adipocytes	(fat	cells,	32).		
Another	feature	of	Thy-1	of	particular	significance	to	TED	is	its	role	as	a	mechano-transducer,	which	
is	achieved	by	its	formation	of	trimolecular	complexes	with	α	and	β	integrins	(33).	Expansion	of	the	
orbital	contents	in	TED	by	adipogenesis	and	over-production	of	ECM,	within	the	confined	bony	orbit,	
leads	to	increased	orbital	pressure;	could	this	influence	fibrosis?		
What	activates	fibrosis	in	TED?	
In	common	with	fibroblasts	in	other	locations	such	as	skin	and	lung,	fibrosis	in	OF	is	upregulated	by	
TGFβ,	a	cytokine	secreted	by	many	cells	including	macrophages	and	fibroblasts	themselves.	Most	in	
vitro	 models	 of	 TED	 pathogenesis	 have	 employed	 2-dimensional	 monolayer	 cultures	 but	 Maryse	
Bailly	 and	 colleagues	 have	 applied	 3-dimensional	 systems	 comprising	 co-cultures	 of	 various	 cell	
types	 in	 collagen	 gels,	 whose	 composition	 can	 be	 varied.	 In	 the	 presence	 of	 TGFβ,	 OF	 from	 TED	
patients	had	 increased	 contractile	properties	 and	proliferation	compared	with	healthy	OF	 (34).	 To	
investigate	the	effect	of	pressure,	OF	were	cultured	in	the	3-D	model	and	pressure,	equivalent	to	28	
mm	mercury	 and	 of	 the	magnitude	 experienced	 in	 TED,	was	 applied.	 The	OF	 from	 both	 TED	 and	
controls,	 started	 to	 acquire	 lipid	 droplets,	 suggesting	 that	 simultataneous	 adipogenesis	 had	 been	
induced,	 simply	 by	 increasing	 the	 pressure.	 The	 Thy-1-low	 population	 preferentially	 accumulated	
lipid,	 whose	 precise	 composition	 is	 being	 ascertained.	 In	 subsequent	 experiments,	 macrophages	
were	 introduced	 into	 the	 3-D	 cultures,	 this	 time	 at	 atmospheric	 pressure.	 There	 was	 no	 lipid	
accumulation	 but	 OF	 morphology	 was	 changed	 with	 increases	 in	 expression	 of	 F-actin	 and	 HA	
production,	 in	 an	 IGF1R	 independent	 manner.	 The	 macrophages	 also	 promoted	 a	 contractile	
phenotype	in	the	OF	but	no	increase	in	expression	of	α-SMA.	All	these	effects	were	more	marked	in	
TED	than	healthy	control	OF	and	mediated	in	part	by	PI3kinase	(35).	
In	recent	years	it	has	been	recognised	that	several	T	cell	subsets	are	implicated	in	autoimmunity.	In	
addition	 to	 well-characterised	 Th1	 (cell-mediated	 immunity)	 and	 Th-2	 (humoral	 immunity)	 cells,	
increased	numbers	of	 the	Th17	subset	have	been	detected	at	 the	site	of	autoimmune	 lesions,	e.g.	
multiple	sclerosis	plaques	(36).		Fang	and	colleagues	reported	that	circulating	Th17	cells,	and	one	of	
their	 cytokines	 IL17A,	were	 increased	 in	TED	patients	 compared	with	healthy	 controls.	 In	 addition	
TED	orbits	were	infiltrated	by	CD4+	and	CD8+	cells	and	displayed	higher	expression	of	IL17-receptor	
and	 IL17A	 which	 were	 associated	 with	 fibrotic	 change.	 Subsequent	 in	 vitro	 studies	 revealed	 that	
IL17A	 stimulated	 production	 of	 ECM	 in	 OF,	 via	 the	 MAPK	 pathway.	 IL17A	 also	 stimulated	 pro-
inflammatory	 cytokine	 production	 (e.g.	 IL6,	 IL8)	 by	 OF,	 which	 would	 exacerbate	 lymphocytic	
infiltration.	 Finally	 a	 product	 isolated	 from	 traditional	 Chinese	medicine	 (Vialinin	 A)	was	 found	 to	
inhibit	 RorγT,	 a	 transcription	 factor	 which	 drives	 Th17	 differentiation,	 and	 thus	 reduced	 their	
numbers	(37).	
The	authors	then	investigated	the	effects	of	IL17A	on	Thy-1+/CD90+	OF	and	Thy-1-/CD90-	OF.	Their	
results	 indicated	 that	 IL17A	 increased	 TGFβ-induced	 fibrosis	 in	 the	 former	 but	 inhibited	 PPARγ	
ligand-induced	adipogenesis	 in	 the	 latter.	However	 IL17A	promoted	secretion	of	pro-inflammatory	
cytokines	by	both	OF	subsets,	especially	prostaglandin	E2,	which	in	turn	increased	differentiation	of	
Th17	cells	(38).	
T	cells	and	the	gut	microbiota	–	what	can	in	vivo	models	tell	us?	
Differentiation	 of	 Th17	 cells,	 which	 promote	 autoimmunity,	 is	 closely	 related	 to	 formation	 of	
regulatory	T	cells	(Treg),	which	dampen	autoimmune	responses.	Both	depend	on	TGFβ	with	IL23	and	
TNFα	being	required	for	differentiation	of	Th17;	the	balance	between	Th17	and	Treg	can	pre-dispose	
an	individual	to	autoimmune	disease	(39).		
Much	TED	 research	 in	 recent	 years	 has	 focussed	on	 the	 end	 stages	of	 disease	 and	 relatively	 little	
progress	 has	 been	 made	 in	 understanding	 the	 mechanisms	 which	 break	 tolerance	 to	 the	 TSHR.	
Several	hypotheses	propose	that	micro-organisms	might	be	implicated,	either	via	molecular	mimicry	
or	 bystander	 activation	 (40).	 These	 hypotheses	 have	 been	 modified	 by	 the	 recognition	 that	
commensal	organisms	in	the	gut	microbiota	secrete	metabolites,	which	influence	the	phenotype	of	T	
cells	 in	 the	 gut	 associated	 lymphoid	 tissue	 (GALT).	 Approximately	 50%	of	 circulating	 T	 cells	 reside	
within	 the	 gut	 at	 any	 time	 and	 studies	 in	 murine	 models	 of	 autoimmunity	 and	 human	 disease	
suggest	 that	 the	 gut	microbiota	may	 influence	 the	 balance	 between	 inflammatory	 Th17	 and	 anti-
inflammatory	Treg	(41,	42).	
In	other	autoimmune	conditions,	in	vivo	models	have	provided	insight	into	the	processes	leading	to	
loss	of	tolerance.	My	own	experience	with	a	TSHR-induced	model	(genetic	immunization)	of	GD/TED	
was	 frustrating,	whilst	we	were	 able	 to	 transfer	 disease	 to	 naïve	 female	 BALB/c	mice	 using	 TSHR	
primed	T	cells	in	one	location	(43),	we	were	not	able	to	reproduce	the	model	in	another	laboratory	
(44);	 neither	 animal	 unit	was	 specific	 pathogen	 free.	Anja	 Eckstein	 and	her	 co-workers	have	been	
able	 to	 reproduce	 a	model	 (17)	 established	 by	 Sajad	Moshkelgosha	 in	 Paul	 Banga’s	 lab	 (16).	 The	
model	uses	genetic	immunization	and	in	vivo	electroporation	of	the	TSHR	and	although	immunized	
mice	developed	signs	of	GD	and	a	TED-like	disease,	there	were	some	differences	e.g.	higher	levels	of	
thyroxine	in	one	centre,	increased	TSHR	autoantibodies	in	the	other.		
Analysis	of	 the	gut	microbiota	 in	 the	2	centres	revealed	significant	differences	 in	α	and	β	diversity	
and	 we	 identified	 disease-associated	 taxonomies,	 which	 support	 a	 role	 for	 the	 gut	 microbiota	 in	
shaping	the	autoimmune	response	(45).	Subsequent	experiments	employed	antibiotic	(vancomycin),	
probiotic	(LAB4,	2	strains	of	Lactobacilli	and	2	strains	of	Bifidobactera)	or	human	TED	faecal	material	
transfer	 (hFMT)	 to	 modify	 the	 gut	 microbiota	 in	 TSHR	 immunized	 mice.	 	 Vancomycin	 treatment	
significantly	reduced	gut	microbiota	richness	and	diversity	compared	with	all	other	groups,	Lab4	and	
hFMT	 had	 more	 subtle	 effects;	 hFMT	 induced	 a	 human	 TED-like	 gut	 microbiota.	 Incidence	 and	
severity	of	induced	thyroid	pathology	(TSAB,	elevated	T4,	hyperplastic	thyroid)	and	orbitopathy	were	
increased	 by	 Lab4	 and	 hFMT	 treatment	 but	 significantly	 reduced	 by	 vancomycin.	 In	 orbital	 lymph	
nodes	 CD25+	 Treg	 numbers	 were	 significantly	 lower/higher	 in	 antibiotic	 and	 probiotic	 treated	
animals	 respectively.	 	 The	manipulation	 strategies	 successfully	modified	 the	 gut	microbiota	 in	 the	
early-stage	 of	 life,	 with	 an	 impact	 on	 TSHR-induced	 disease.	 The	 reduced	 thyroid	 and	 orbital	
pathology,	combined	with	diminished	Tregs,	 in	vancomycin	treated	mice	support	a	role	for	the	gut	
microbiota	in	promoting	TED	(ms	submitted).	
Do	we	see	changes	in	the	gut	microbiota	in	patients?	
The	 experiments	 described	 above	were	 part	 of	 a	 larger	 project	 to	 investigate	 the	 role	 of	 the	 gut	
microbiome	 in	 GD	 and	 TED	 http://www.indigo-iapp.eu/	 and	 which	 has	 also	 analysed	 the	 gut	
microbiota	 composition	 of	 human	 subjects.	We	observed	 similar	 perturbations	 in	 people	with	GD	
and	 TED	 as	mice	with	 TSHR-induced	 disease;	 for	 example,	 reduced	 Firmicutes	 (F)	 phylum	 counts;	
significantly	 increased	 Bacteroidetes	 (B)	 phylum	 counts;	 significantly	 increased	 F:B	 ratio.	
Actinobacter	phylum	counts	were	significantly	higher	 in	people	with	mild	TED	 than	 in	GD	patients	
free	 of	 eye	 disease.	 However,	 it	 may	 be	 difficult	 to	 distinguish	 the	 contributions	 of	 endocrine	
(hyperthyroidism)	and	immune	(TSAB)	factors	to	the	changes	observed	(ms	in	preparation).		
The	 Firmicutes	 phylum	 includes	 Clostridium	 species	 and	 these	 butyrate	 producing	 bacteria	 have	
been	 implicated	 in	 a	mouse	model	 of	 hepatic	 fibrosis	 (46).	 Furthermore	 species	 in	 the	 nasal	 and	
sinus	microbiomes	may	secrete	metabolites	which	influence	orbital	inflammation	and	fibrosis.	
Of	note,	changes	in	the	gut	microbiome	due	to	smoking	overlapped	those	identified	for	TED	but	not	
in	GD	patients	or	healthy	controls.	Smoking	is	the	single	biggest	known	environmental	risk	factor	for	
TED	incidence	and	severity	(6)	and	is	known	to	affect	the	gut	microbiota	composition	(47)	
Concluding	comments	
Fibrosis	 remains	 one	 of	 the	 biggest	 challenges	 facing	 patients	 with	 TED	 and	 the	 clinicians	 who	
manage	them.	It	causes	disturbance	to	eye	motility	which	has	a	major	negative	impact	on	quality	of	
life	but	we	are	not	aware	of	any	ongoing	or	pending	trials	to	address	this	process.		
The	fact	that	TGFβ	 is	required	for	the	differentiation	of	Th17	cells,	Treg	(whose	balance	 influences	
autoimmunity)	and	myofibroblasts	(which	are	directly	responsible	for	fibrosis)	suggests	that	 it	may	
be	a	useful	target	for	treatment.	
However	 I	 am	 aware	 of	 long-standing	 studies	 by	 Paul	Meyer	 investigating	 antibiotic	 treatment	 of	
TED	patients	found	to	harbour	S	Aureus	infection;	the	results	are	eagerly	anticipated.	
Finally,	 resolution	 of	 fibrosis	 depends	 on	 interactions	 between	 CD90/Thy-1	 and	 Fas	 to	 promote	
apoptosis	(48),	is	TED	a	disease	of	apoptosis	resistant	myofibroblasts?	
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